TMCnet News
Burns - Pipeline Review, H2 2017 - Research and MarketsThe "Burns - Pipeline Review, H2 2017" report has been added to Research and Markets' offering. Burns - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Burns (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Burns (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Burns and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 3, 4, 1, 14, 5 and 1 respectively. Similarly, the Universities portfolio i Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Burns (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Key Topics Covered:
For more information about this report visit https://www.researchandmarkets.com/research/hfdhq3/burns_pipeline
View source version on businesswire.com: http://www.businesswire.com/news/home/20170913006070/en/ |
